The European Commission has approved a higher dose of Novo Nordisk's 7.2 mg injectable drug Wegovy (semaglutide) for the treatment of obesity in adults.[2] This approval followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in December 2025.[2] The drug is now available in all 27 countries of the European Union, and doctors can move patients directly from the 2.4 mg dose to the 7.2 mg dose if they need more weight loss.[2] In the 72-week STEP UP clinical trial of 1,407 adults without diabetes, patients on the 7.2 mg dose lost an average of 20.7% of their body weight compared to 17.5% on the 2.4 mg dose.[3] About a third of the participants achieved weight loss of 25% or more.[4] Novo Nordisk has filed for approval of a 7.2 mg single syringe that could be available this year.[2]